Biointron published a study showing structure-guided disulfide engineering restricted Fab movement in human IgG2 to produce meaningful gains in CD40 and 4-1BB agonism.
Public source
Publisher name
Public post
Same Binding, Different Biology: Biasing Antibody Conformation for Productive Receptor Signaling Antibody engineering has traditionally focused heavily on the binding ev…
Company
Biointron
Recombinant Antibody Expression, Delivery in 2 weeks (From Gene Sequence to Purified Antibody)
- Industry
- Biotechnology Research
- Location
- Zhoupu Town, Pudong New District, CN
- Company size
- 11–50 employees
About Biointron
About Biointron: Founded in 2012 Certified to ISO 9001:2015 High-technology Enterprises CRO supplier for antibody discovery and expression Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization for global biotech and pharmaceutical companies. Biointron holds a leading position in the antibody expression industry. From gene sequence to purified antibodies, it only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 3,000 biotech and pharma companies worldwide. We provide antibody discovery, expression and optimization services, including VHH antibody discovery, single B-cell antibody screening, hybridoma sequencing, antibody humanization, antibody affinity maturation, and RushData (an AI antibody wet lab validation service that provides high-throughput wet lab validation for AI/ML-designed antibody candidates, turning computational predictions into experimentally confirmed data). Additionally, Biointron holds global sublicensing rights for ECACC's CHO-K1. Our CHOK1BN cell line, which is derived from CHO-K1, has been filed in the DMF system with the US FDA. By choosing the CHOK1BN cell line, several partners' projects have entered multicenter international clinical trials successfully. For more information, please visit our official website at www.biointron.com or contact us at info@biointron.com
See moreLatest activity
Latest activity from Biointron
8 signals
Presence & Recognition
Biointron is exhibiting at booth #6 at The Westin Boston Seaport in Boston, Massachusetts, on September 15 to 17, 2026, for a conversation about bsAbs.
Research & Knowledge
Biointron published a recent review describing the required regulatory deliverables and a roadmap for sequencing key workstreams for ADCs.
Products & Services
Biointron launched the RushData Assay Discount Bundle for new customers to save on antibody candidates.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Biocytogen
Biocytogen published a new Nature Biotechnology study reporting AIntibody, a prospective, blinded benchmark testing 511 AI-designed or AI-selected antibodies from 29 organizations with every submission experimentally evaluated for affinity and developability.
Research & Knowledge
Invenra
Invenra published a paper describing the biophysical properties of the B-Body® bispecific antibody platform, with forced degradation studies revealing favorable stability of bispecific antibodies generated using the platform.
Research & Knowledge
evitria AG
evitria AG published a paper of the week titled A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developability.
Research & Knowledge
ACROBiosystems
ACROBiosystems published a case study series exploring practical applications in drug development, beginning with ADCC and ADCP functional validation in antibody drug development.
Research & Knowledge
Rondo Therapeutics